Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Hairy cell leukemia]]== | ==[[Hairy cell leukemia]]== | ||
| − | # Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. [https://www.ncbi.nlm.nih.gov/pubmed/22355053 PubMed] | + | # '''Phase 1:''' Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. [http://ascopubs.org/doi/abs/10.1200/JCO.2011.38.1756 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383181/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22355053 PubMed] |
| + | ## '''Update:''' Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018 May 24;131(21):2331-2334. Epub 2018 Feb 27. [http://www.bloodjournal.org/content/131/21/2331.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29487070 PubMed] | ||
=Also known as= | =Also known as= | ||
Revision as of 02:59, 30 May 2018
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Preliminary data
Hairy cell leukemia
- Phase 1: Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. link to original article link to PMC article PubMed
- Update: Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018 May 24;131(21):2331-2334. Epub 2018 Feb 27. link to original article PubMed
Also known as
- Code name: CAT-8015